Rise and shine, everyone, the middle of the week has arrived. And this calls for a celebratory cup or two of stimulation. How so? Well, you made it this far, which can be an accomplishment, after all. Moreover, there is always good reason to forge ahead, given that there is so much more to do and the effort just might pay off. With this in mind, we have assembled the usual menu of tidbits for your perusal. Hope you have a smashing day and do drop us a line when you run across something interesting …
Dr. Craig Thompson, the chief executive of Memorial Sloan Kettering Cancer Center, plans to resign his seats on the boards of Merck (MRK) and Charles River Laboratories (CRL), The New York Times reports. The decision is the latest fallout from a widening institutional reckoning over relationships between cancer center leaders and for-profit health care companies. Thompson, 65, received $300,000 in compensation from Merck in 2017, and was paid $70,000 in cash by Charles River last year, plus $215,050 in stock.
About the Author Reprints
In the matter of the final item, why do I seem to hear the Regeneron worthies say “Rats!” in reaction to this turn of events?